Current Agreements Deals Update:April 2011

     Forward to a Friend

Welcome to the April 2011 edition of Current Agreements Deals Update.

This month we are providing you with an overview of deal making activity in the life sciences, covering  partnering and M&A in March 2011.

Deal of the month

Collaborative R&D and licensing agreement for phosphodiesterase type 1 (PDE1) inhibitors

Takeda, Intra-Cellular Therapies - March 3, 2011

Exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors, discovered by ITI, for the treatment of cognitive impairment associated with schizophrenia more

Breaking news...

Deals of note just announced in the past few days:

Collaborative R&D and licensing agreement for Anticalins therapeutics
Daiichi Sankyo, Pieris - 12 April 2011

Collaborative R&D agreement for single G-protein coupled receptor (GPCR) discovery program
Takeda, Heptares Therapeutics - 11 April 2011

Acquisition agreement for American Medical Systems
Endo, American Medical Systems - 11 April 2011

For more breaking deals as they are announced, visit: http://www.currentagreements.com

Month in review Deal of the month Partnering - March 2011 M&A - March 2011 The Top Ten Bigpharma Partnering Deals Update Articles

Month In Review

Welcome to the April 2011 edition of Current Agreements Deals Update.

This month we are providing you with an overview of deal making activity in the life sciences, covering partnering and M&A in March 2011.

As we move into spring, partnering activity appears to continue at a good pace. A total of 299 partnering deals were announced during the month, with the top deal by value being the collaborative R&D and licensing agreement between Takeda and Intra-Cellular Therapies for PDE1 inhibitors. The deal had a headline value of $750million. Further details can be viewed here.

M&A also saw significant activity, with the leading deal being the proposed acquisition of Cephalon by Valeant for $5.7 billion. Full details here.

With the emerging role of personalized medicine in recent dealmaking we have published a series of reports:

• Personalized Medicine Partnering Terms and Agreements
• Biomarker Partnering Terms and Agreements
• Companion Diagnostics Partnering Terms and Agreements
• Pharmacogenomic Partnering Terms and Agreements

With a new year, comes a brand new set of Scorecards for 2011: Top partnering deals 2011 | Top M&A deals 2011. Each has already been populated with the leading deals of the year - check them out.

In addition, we have also published our 2010 Yearbook - detailing every deal announced during the past 12 months - Full details at: Partnering Agreements in Pharma and Biotech Yearbook 2010.

A complete list of top partnering and M&A deals by value for 2010 are still available and can be viewed at: Top partnering deals 2010 | Top M&A deals 2010 | Biggest dealmakers of 2010

We welcome your comments and feedback on this newsletter. We also welcome contact from any company has a deal not already announced by press release, allowing us to add non-publicized deals to the database.

Regards

Steve Poile

The Top Ten

The following are the top 10 deals and alliances by value, as announced in March 2011.

1. Collaborative R&D and licensing agreement for phosphodiesterase type 1 (PDE1) inhibitors - Takeda, Intra-Cellular Therapies - $750m

2. Development and licensing agreement for FP-1039 - Five Prime Therapeutics, Human Genome Sciences - $495m

3. Development and licensing agreement for obeticholic acid (INT-747) - Dainippon Sumitomo, Intercept - $315m

4. Collaborative R&D and licensing agreement for small molecules that target T-helper 17 (Th17) cells - Merck & Co, Lycera - $307m

5. Development, licensing and supply agreement for Xiaflex - Asahi Kasei, Auxilium - $262m

6. Grant award for long-acting single-dose antiviral drug - Biota, BARDA - $231m

7. Collaborative R&D agreement for antibody-drug conjugate (ADC) technology with antibodies to a single oncology target - Abbott, Seattle Genetics - $208m

8. Collaborative R&D, development and licensing agreement for therapeutics targeting EZH2 - Eisai, Epizyme - $206m

9. Co-development and licensing agreement for lurasidone - Takeda, Dainippon Sumitomo - $180m

10. Collaborative R&D agreement for oncology research - Gilead Sciences, Yale University - $100m

Full details of each deal available at Current Agreements*
*Subscription required

Bigpharma Partnering

March saw 49 partnering deals announced where bigpharma were at least one of the parties to the deal. This is up from the 34 deals recorded in the previous month.

Japanese companies including Takeda, Astellas, Dainippon Sumitomo and Eisai were particularaly active with eight deals between them.

For Dainippon Sumitomo the key deal was signed with Intercept Pharmaceuticals for obeticholic acid (INT-747).

The key terms were:

• Exclusive licensing agreement for the development and commercialization of Intercept's first-in-class FXR agonist obeticholic acid (OCA, also known as INT-747).
• DSP will advance OCA in Japan and China for the treatment of chronic liver diseases, with an initial focus on primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH).
• Intercept is currently preparing for the initiation of a Phase III PBC program in the US and Europe and, under the company's cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a large placebo-controlled trial of OCA in NASH patients recently started enrolling in the US.
• Intercept will receive an initial payment from DSP of $15 million and will be eligible to receive approximately $300 million in additional milestone payments associated with the successful development and commercialization of OCA.
• Upon launch of OCA, Intercept will be entitled to receive tiered double-digit royalties from DSP based on sales in its territory.
• DSP has the exclusive option to add several other Asian countries to its territory, including Korea and Taiwan, and to pursue additional indications.
• DSP will be responsible for the costs of developing and commercializing OCA in its territory.

For Takeda the key deal was signed with Intra-Cellular Therapies for collaborative R&D and licensing agreement for phosphodiesterase type 1 (PDE1) inhibitors.

The key terms were:

• Exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors, discovered by ITI, for the treatment of cognitive impairment associated with schizophrenia.
• This agreement is targeted worldwide, but ITI has retained the option to co-promote with Takeda in the United States.
• ITI will receive an upfront cash payment and will be eligible to receive payments of approximately $500 million in the aggregate upon achievement of certain development milestones and up to an additional $250 million in the aggregate upon achievement of certain sales-based milestones, along with tiered royalty payments based on net sales by Takeda.
• Takeda will be solely responsible for development, manufacturing and commercialization of PDE1 inhibitors.

Deal Update Articles

Recent deals and alliances in life sciences - here's our take:

Valeant turns hostile in pursuit of Cephalon

Valeant CEO Michael Pearson sounded the start gun in what might turn out to be a prolonged hostile bid for Cephalon when he publisized correspondence between the companies on Valeant's private approach to acquire Cephalon.

The rise of the asset auction

Recent days have seen a number of announcements of pending auctions of IP in what is becoming a trend in the biopharma sector.

Cephalon snags Gemin X for lung cancer drug

Cephalon is once again on the acquisition trail - this time paying $225 million in cash plus milestones of $300 million for Gemin X should its lead product candidate, obatoclax successfully reach market.

Will Respira Health's offer derail Precision Therapeutic's licensing of LungExpress Dx?

In an unusual move, Respira Health have tabled a rival licensing proposal for Med BioGene's LungExpress Dx diagnostic used to improve staging for identifying those patients wiht early stage non-small-cell lung cancer.

Terumo acquisition of CaridianBCT is largest ever in Japanese medical devices sector

Terumo has announced it is to acquire the US medical device company, CaridianBCT from Gambro in a deal valued ta $2.6 billion, making it the biggest ever medical device acquisition by a Japanese company.

Subscribing to Current Agreements

Fees for 12 months access:

• $3000 for an individual subscription
• Add a colleague for $500
• $15000 for company wide access

Subscribe now

More details
 

REQUEST A FREE TRIAL

Did you know you can request a free trial of Current Agreements?

Simply go to our Trial page and let us know when you would like to trial the database.

REQUEST TRIAL

NEW: Personalized Medicine Partnering Terms and Agreements

The Personalized Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

Buy now | View more details

Current Agreements statistics

Total numbers of deals since 2000:

• Partnering: 15,105
• M&A: 1,790
• Companies: 11,111

Partnering - March 2011

A total of 299 partnering deals were announced during March 2011.

By industry sector:

Bigpharma: 49
Pharmaceuticals: 105
Biotechnology: 72
Diagnostic: 30
Drug delivery: 8
Medical Device: 48
Research tools: 93
Consumer health: 12
Specialty pharma: 10
Generic pharma: 1
Animal health: 7
Agricultural: 7
Academic: 40
Non profit: 38
Government: 15
Services: 91

By stage of development:

Discovery: 55
Pre-clinical: 40
Phase I: 22
Phase II: 17
Phase III: 5
Regulatory: 0
Marketed: 27
Formulation: 9

By therapy area:

Hospital care: 21
Cardiovascular: 11
Central Nervous System: 31
Cosmetics: 1
Dental: 3
Dermatology: 7
Gastrointestinal: 9
Genetic: 1
Genitourinary: 7
Hematology: 5
Hormonal: 0
Immunology: 8
Infectives: 21
Inflammatory: 9
Metabolic: 17
Musculoskeletal: 14
Oncology: 46
Ophthalmics: 7
Respiratory: 7
Sensory organ: 0

Full details available at Current Agreements*
*Subscription required

M&A - March 2011

A total of 54 M&A deals were announced during March 2011.

By industry sector:

Bigpharma: 5
Pharmaceuticals: 12
Biotechnology: 6
Diagnostic: 3
Drug delivery: 0
Medical device: 26
Research tools: 8
Consumer health: 1
Specialty pharma: 1
Generic pharma: 0
Animal health: 0
Agricultural: 0
Services:22

Full details available at Current Agreements*
*Subscription required

Note: Deals tend to have multiple categories and therefore appear more than once.